Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178048 | 0.82 | ALDH1A1 (0.43) | SCN5ASCN3AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL5160587 | 0.82 | ALDH1A1 (0.43) | SCN5ASCN3AL3MBTL1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL5160519 | 0.81 | ALDH1A1 (0.42) | SCN5ASCN3AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL14371776 | 0.80 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGD | |
| SCHEMBL5158325 | 0.80 | ALDH1A1 (0.32) | ALDH1A1MAPTHPGD | |
| SCHEMBL14371698 | 0.79 | UCHL1 (0.37) | SCN5ASCN3A | |
| SCHEMBL14371716 | 0.79 | UCHL1 (0.37) | SCN5ASCN3A | |
| SCHEMBL14400254 | 0.79 | GPR119 (0.34) | SCN5ASCN3AL3MBTL1GLSALDH1A1 | |
| SCHEMBL5160579 | 0.78 | CYP1A2 (0.37) | ALDH1A1HDAC1 | |
| SCHEMBL14371739 | 0.78 | GCK (0.32) | SCN5ASCN3AALDH1A1ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | SCN5A 86/4885SCN3A 93/4885NR1H2 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.